Download PDF

1. Company Snapshot

1.a. Company Description

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh.The company offers allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies.It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids.


The company also exports its products.Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.

Show Full description

1.b. Last Insights on BXP

Beximco Pharmaceuticals Limited's recent performance was driven by the company's focus on its core pharmaceutical business. The Bangladeshi government's decision to permanently close a dozen Beximco Apparel factories, which was announced on January 30, 2025, is a positive development for the company. This move allows Beximco to refocus on its pharmaceutical business, which has been performing well. The company's strong sales and revenue growth in recent quarters, driven by the demand for its generic medicines, are also expected to continue. Additionally, the company's efforts to expand its product portfolio through strategic acquisitions and partnerships are likely to drive future growth.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Bangladeshi Government to Permanently Close a Dozen Beximco Apparel Factories

Jan -30

Source:

Card image cap

Foreign Investors Express Interest in Buying Beximco Subsidiaries

Oct -22

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.50%)

6. Segments

Pharmaceutical Formulations and Active Pharmaceutical Ingredients

Expected Growth: 8.5%

Strong demand for generic medicines, increasing access to healthcare in Bangladesh, and Beximco's cost-effective production capabilities drive growth in Pharmaceutical Formulations. Meanwhile, the company's focus on R&D, strategic partnerships, and compliance with international quality standards boost Active Pharmaceutical Ingredients segment, resulting in an overall growth rate of 8.5%.

7. Detailed Products

Antibiotics

Beximco Pharmaceuticals Limited offers a wide range of antibiotics to treat bacterial infections, including cephalosporins, macrolides, and fluoroquinolones.

Anti-Ulcerants

The company's anti-ulcerant products are designed to treat gastrointestinal disorders, including gastroesophageal reflux disease (GERD) and peptic ulcers.

Antihistamines

Beximco's antihistamine products are used to treat allergic reactions, including itching, sneezing, and runny nose.

Anti-Diabetic

The company's anti-diabetic products are designed to regulate blood sugar levels and manage diabetes.

Cardiovascular

Beximco's cardiovascular products are used to treat high blood pressure, high cholesterol, and other cardiovascular conditions.

Neurology

The company's neurology products are used to treat neurological disorders, including epilepsy, Parkinson's disease, and Alzheimer's disease.

Oncology

Beximco's oncology products are used to treat various types of cancer, including breast, lung, and colon cancer.

Orthopedic

The company's orthopedic products are used to treat musculoskeletal disorders, including osteoarthritis and rheumatoid arthritis.

Respiratory

Beximco's respiratory products are used to treat respiratory disorders, including asthma, chronic obstructive pulmonary disease (COPD), and bronchitis.

8. Beximco Pharmaceuticals Limited's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes is moderate for Beximco Pharmaceuticals Limited, as there are some alternative products available in the market, but they are not highly substitutable.

Bargaining Power Of Customers

The bargaining power of customers is low for Beximco Pharmaceuticals Limited, as the company has a strong brand presence and customers have limited bargaining power.

Bargaining Power Of Suppliers

The bargaining power of suppliers is moderate for Beximco Pharmaceuticals Limited, as the company has a diversified supplier base, but some suppliers have significant bargaining power.

Threat Of New Entrants

The threat of new entrants is high for Beximco Pharmaceuticals Limited, as the pharmaceutical industry is attractive and has low barriers to entry.

Intensity Of Rivalry

The intensity of rivalry is high for Beximco Pharmaceuticals Limited, as the company operates in a highly competitive market with many established players.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 19.55%
Debt Cost 7.12%
Equity Weight 80.45%
Equity Cost 7.12%
WACC 7.12%
Leverage 24.29%

11. Quality Control: Beximco Pharmaceuticals Limited passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Beximco Pharma

A-Score: 8.5/10

Value: 6.8

Growth: 7.4

Quality: 7.2

Yield: 10.0

Momentum: 9.5

Volatility: 10.0

1-Year Total Return ->

View Full Report
Stock-Card
Neurocrine Biosciences

A-Score: 5.8/10

Value: 1.9

Growth: 9.3

Quality: 8.3

Yield: 0.0

Momentum: 8.0

Volatility: 7.0

1-Year Total Return ->

View Full Report
Stock-Card
Ipsen

A-Score: 5.5/10

Value: 5.0

Growth: 6.0

Quality: 7.7

Yield: 1.2

Momentum: 6.0

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
Bumrungrad Hospital

A-Score: 5.5/10

Value: 2.0

Growth: 7.3

Quality: 8.8

Yield: 4.2

Momentum: 1.5

Volatility: 9.3

1-Year Total Return ->

View Full Report
Stock-Card
HUTCHMED

A-Score: 5.5/10

Value: 6.7

Growth: 7.4

Quality: 7.1

Yield: 0.0

Momentum: 4.0

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Viatris

A-Score: 5.3/10

Value: 8.9

Growth: 2.2

Quality: 3.3

Yield: 7.0

Momentum: 3.0

Volatility: 7.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.42$

Current Price

0.42$

Potential

-0.00%

Expected Cash-Flows